CN104684564A - 治疗非小细胞肺癌的方法 - Google Patents

治疗非小细胞肺癌的方法 Download PDF

Info

Publication number
CN104684564A
CN104684564A CN201380030309.9A CN201380030309A CN104684564A CN 104684564 A CN104684564 A CN 104684564A CN 201380030309 A CN201380030309 A CN 201380030309A CN 104684564 A CN104684564 A CN 104684564A
Authority
CN
China
Prior art keywords
oligonucleotide
acrasin
chemotherapy
lung cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380030309.9A
Other languages
English (en)
Chinese (zh)
Inventor
陈·杜克森
索斯·泰斯勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN104684564A publication Critical patent/CN104684564A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380030309.9A 2012-05-18 2013-05-17 治疗非小细胞肺癌的方法 Pending CN104684564A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18
US61/649,092 2012-05-18
PCT/US2013/041652 WO2013173757A1 (en) 2012-05-18 2013-05-17 Method for treating non-small cell lung cancer

Publications (1)

Publication Number Publication Date
CN104684564A true CN104684564A (zh) 2015-06-03

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380030309.9A Pending CN104684564A (zh) 2012-05-18 2013-05-17 治疗非小细胞肺癌的方法

Country Status (17)

Country Link
US (1) US20130310440A1 (enExample)
EP (1) EP2849761A1 (enExample)
JP (1) JP2015522542A (enExample)
KR (1) KR20150024843A (enExample)
CN (1) CN104684564A (enExample)
AR (1) AR091090A1 (enExample)
AU (1) AU2013262589A1 (enExample)
BR (1) BR112014028787A2 (enExample)
CA (1) CA2874092A1 (enExample)
EA (1) EA201492148A1 (enExample)
IL (1) IL235459A0 (enExample)
IN (1) IN2014DN10390A (enExample)
PH (1) PH12014502569A1 (enExample)
SG (1) SG11201407649RA (enExample)
TW (1) TW201402132A (enExample)
UY (1) UY34812A (enExample)
WO (1) WO2013173757A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100820266B1 (ko) 1999-02-26 2008-04-08 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
HUE071973T2 (hu) 2010-05-08 2025-10-28 Univ California Hám alatti nedvességet (sem) érzékelõ berendezés fekélyek korai észlelésére
MX2013010524A (es) 2011-03-15 2013-12-06 Univ British Columbia Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
NZ736278A (en) 2015-04-24 2022-05-27 Bruin Biometrics Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
DK3515296T3 (da) 2017-02-03 2023-11-27 Bbi Medical Innovations Llc Måling af vævslevedygtighed
PT3515306T (pt) 2017-02-03 2025-01-27 Bbi Medical Innovations Llc Medição da suscetibilidade a úlceras do pé diabético
CA3042101C (en) 2017-02-03 2024-04-09 Bruin Biometrics, Llc Measurement of edema
BR112020009676A2 (pt) * 2017-11-16 2020-10-13 Bruin Biometrics, Llc método para fornecer continuidade de atendimento a um paciente durante transferência entre locais de atendimento
WO2019136287A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant chemicals that prevent drug tolerance and persister formation by bacteria
HUE066478T2 (hu) 2018-02-09 2024-08-28 Bruin Biometrics Llc Szöveti károsodás észlelése
EP4489231A3 (en) 2018-10-11 2025-02-19 Bruin Biometrics, LLC Device with disposable element
MX2023009108A (es) 2021-02-03 2023-08-09 Bruin Biometrics Llc Métodos de tratamiento de daño tisular inducido por presión en estadio profundo y temprano.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166591A1 (en) * 1999-02-26 2003-09-04 Martin Gleave TRPM-2 antisense therapy using an oligonucleotide having 2'-O-(2-methoxy)ethyl modifications
US20080119425A1 (en) * 2004-04-02 2008-05-22 The University Of British Columbia Clusterin Antisense Therapy for Treatment of Cancer
CN103958681A (zh) * 2011-05-19 2014-07-30 泰华制药工业有限公司 治疗非小细胞肺癌的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2009155381A1 (en) * 2008-06-18 2009-12-23 Abbott Laboratories P/gf-1 companion diagnostic methods and products

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166591A1 (en) * 1999-02-26 2003-09-04 Martin Gleave TRPM-2 antisense therapy using an oligonucleotide having 2'-O-(2-methoxy)ethyl modifications
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20080119425A1 (en) * 2004-04-02 2008-05-22 The University Of British Columbia Clusterin Antisense Therapy for Treatment of Cancer
CN103958681A (zh) * 2011-05-19 2014-07-30 泰华制药工业有限公司 治疗非小细胞肺癌的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANNAMARIA BIROCCIO ET AL.: "The future of antisense therapy: combination with anticancer treatments", 《ONCOGENE》 *
KIMN. CHI ET AL.: "APhase IStudy ofOGX-011, a 2¶-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combinationwith Docetaxel in Patients with Advanced Cancer", 《CLIN. CANCWE RES.》 *
LAURA V. JULY ET AL.: "Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo", 《MOLECULAR CANCER THERAPEUTICS》 *

Also Published As

Publication number Publication date
AR091090A1 (es) 2014-12-30
IN2014DN10390A (enExample) 2015-08-14
KR20150024843A (ko) 2015-03-09
BR112014028787A2 (pt) 2017-06-27
CA2874092A1 (en) 2013-11-21
EA201492148A1 (ru) 2015-04-30
WO2013173757A8 (en) 2015-04-30
UY34812A (es) 2013-12-31
US20130310440A1 (en) 2013-11-21
TW201402132A (zh) 2014-01-16
JP2015522542A (ja) 2015-08-06
PH12014502569A1 (en) 2015-01-21
AU2013262589A1 (en) 2015-01-22
SG11201407649RA (en) 2014-12-30
IL235459A0 (en) 2014-12-31
WO2013173757A1 (en) 2013-11-21
EP2849761A1 (en) 2015-03-25

Similar Documents

Publication Publication Date Title
CN104684564A (zh) 治疗非小细胞肺癌的方法
CN103958681A (zh) 治疗非小细胞肺癌的方法
JP5926724B2 (ja) がんを処置する方法
Reardon et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma
Gatzemeier et al. Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
RU2480211C2 (ru) Лечение рака молочной железы с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами
Tolcher et al. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer
JP6242213B2 (ja) 薬物送達および治療用薬剤の有効性を向上させる方法
CN107923918A (zh) 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法
KR20140009275A (ko) 파클리탁셀 및 트라스투주맙-mcc-dm1에 의한 her2-양성 암의 치료
KR20200014298A (ko) Her2 양성 암의 치료
CN107750165A (zh) 借助塞里班土单抗的组合治疗
Yamada et al. A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer
Sun et al. Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers
Wang et al. Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD‐1 and VEGF, in Chinese Patients With Advanced Solid Tumors
Chen et al. Intraperitoneal PD-1 monoclonal antibody for the treatment of advanced primary liver cancer with malignant ascites: a single-arm, single-center, phase Ib trial
Qu et al. Camrelizumab combined with apatinib for unresectable, metastatic esophageal squamous cell carcinoma: a single-center, single-arm, prospective study
Ko et al. Jingyue Qiu1, Dandan Sheng1, Fei Lin2, 3*, Peng Jiang4 and Ning Shi1
Mantrana et al. A phase 1b study of CBP501, a novel immunogenic cell death inducer, combined with cisplatin and nivolumab in patients with advanced solid tumors
WO2025251009A1 (en) Methods of treating bladder cancer using an oncolytic virus and a transduction-enhancing agent
WO2025251014A1 (en) Methods and compositions for biomarker-guided bladder cancer therapy
Stroes Precision oncology in esophagogastric cancer
Matrana et al. British Journal of Cancer Research

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150603

WD01 Invention patent application deemed withdrawn after publication